Summary
This brief provides background information on the Centers for Medicare and Medicaid Services’ (CMS) Medicare Part B Drug and Biological Competitive Acquisition Program (CAP). Although the program is no longer in operation, the Center for Medicare and Medicaid Innovation (CMMI) renewed attention on the program by requesting comment on it as part of the Medicare Part B Drug Payment Model proposed rule. The agency cited the possibility of the program’s inclusion as a policy alternative in future CMMI reimbursement models. This brief reviews the CAP model’s key aspects, lessons learned from its prior iterations, and current policy considerations.